Glass House Brands (GLAS) Cash from Investing Activities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Cash from Investing Activities came in at -$2.7 million in Q1 2026, up 58.98% year-on-year from -$1.7 million in Q1 2025, and down 26.08% on a QoQ basis from -$2.2 million in Q4 2025.
Glass House Brands (GLAS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Cash from Investing Activities data on file, last reported at -$2.7 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 58.98% year-over-year to -$2.7 million in Q1 2026; TTM through Mar 2026 was -$23.8 million, a 63.14% decrease from a year earlier, with the FY2025 full-year figure at -$27.7 million, down 169.5% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$2.7 million, down from -$2.2 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for GLAS reached as high as $13.0 million in Q1 2022 and fell as low as -$12976.5 billion in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$1143.1 billion across 5 years, with a median of -$2.4 million in 2024.
- Across the five-year window, Cash from Investing Activities soared 2198.29% in 2022 and sank 19738531056.36% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at -$12976.5 billion in 2022, then surged by 100.0% to $6.3 million in 2023, then slumped by 140.91% to -$2.6 million in 2024, then gained by 14.92% to -$2.2 million in 2025, then decreased by 26.08% to -$2.7 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$2.7 million in Q1 2026, -$2.2 million in Q4 2025, and -$9.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.75 Mn |
| Mar 31, 2026 | -2.75 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -9.60 Mn |
| Sep 30, 2025 | -9.60 Mn |
| Jun 30, 2025 | -9.27 Mn |
| Jun 30, 2025 | -9.27 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Mar 31, 2025 | -6.70 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Dec 31, 2023 | 6.26 Mn |
| Dec 31, 2023 | 6.26 Mn |